Meredith McKean

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 739 citations

Life Sciences, Immunology, Oncology +14

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 658 citations · Full text

Medicine, Dermatology, Oncology +14

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky et al. · Journal of Clinical Oncology · 2022 · 186 citations

Medicine, Oncology, Pharmacology +16

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Özgün et al. · Journal for ImmunoTherapy of Cancer · 2017 · 134 citations · Full text

Medicine, Hematology, Oncology +17

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.

Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy et al. · Journal of Clinical Oncology · 2023 · 68 citations

Medicine, Oncology, Pharmacology +14